Open-label, Single-arm, Phase 2 Study of the Initial and Post-Transplant Treatment With Carfilzomib, Lenalidomide and Low Dose Dexamethasone (CRd) in Transplant Candidates With Newly Diagnosed, Multiple Myeloma Requiring Systemic Chemotherapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 May 2019
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 22 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 22 May 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Apr 2018.